Technical Analysis for NVAX - Novavax, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 1.64% | |
| Oversold Stochastic | Weakness | 1.64% | |
| 20 DMA Resistance | Bearish | -4.12% | |
| Bollinger Band Squeeze | Range Contraction | -4.12% | |
| Stochastic Reached Oversold | Weakness | -4.12% | |
| BB Squeeze Started | Range Contraction | -4.12% | |
| Oversold Stochastic | Weakness | -4.12% | |
| 20 DMA Resistance | Bearish | -1.41% | |
| Outside Day | Range Expansion | -1.41% | |
| Wide Bands | Range Expansion | -1.41% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | 31 minutes ago |
| Possible Inside Day | 31 minutes ago |
| Down 1% | about 4 hours ago |
| Up 2% | about 5 hours ago |
| Up 1% | about 5 hours ago |
Get a Trading Assistant
- Earnings date: 02/27/2023
Novavax, Inc. Description
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Infectious Diseases Clinical Development Influenza Vaccines Coronavirus Vaccination Influenza Vaccine Rabies Seasonal Influenza
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 101.39 |
| 52 Week Low | 8.75 |
| Average Volume | 7,090,568 |
| 200-Day Moving Average | 34.05 |
| 50-Day Moving Average | 13.65 |
| 20-Day Moving Average | 11.52 |
| 10-Day Moving Average | 11.56 |
| Average True Range | 1.09 |
| RSI | 39.02 |
| ADX | 12.07 |
| +DI | 23.06 |
| -DI | 23.94 |
| Chandelier Exit (Long, 3 ATRs) | 10.43 |
| Chandelier Exit (Short, 3 ATRs) | 12.02 |
| Upper Bollinger Bands | 12.94 |
| Lower Bollinger Band | 10.09 |
| Percent B (%b) | 0.2 |
| BandWidth | 24.79 |
| MACD Line | -0.60 |
| MACD Signal Line | -0.70 |
| MACD Histogram | 0.1025 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.85 | ||||
| Resistance 3 (R3) | 11.92 | 11.58 | 11.65 | ||
| Resistance 2 (R2) | 11.58 | 11.28 | 11.55 | 11.58 | |
| Resistance 1 (R1) | 11.12 | 11.09 | 10.95 | 11.05 | 11.52 |
| Pivot Point | 10.78 | 10.78 | 10.70 | 10.75 | 10.78 |
| Support 1 (S1) | 10.32 | 10.48 | 10.15 | 10.25 | 9.78 |
| Support 2 (S2) | 9.98 | 10.29 | 9.95 | 9.72 | |
| Support 3 (S3) | 9.52 | 9.98 | 9.65 | ||
| Support 4 (S4) | 9.45 |
